Parallel Session V: Outcomes
Malignancies in Patients with AAV Treated Within the EUVAS Trials
Dr. Beatriz Sánchez Álamo
#Vasculitis22
Future cancer risk is a concern with immunosuppression for AAV.
ncbi.nlm.nih.gov/pmc/articles/P…
#Vasculitis22
Aims of this were to analyse results from extended follow up of patients who participated in EUVAS prospective RCTs.
#Vasculitis22
Data collection with online surveys.
ICD coding.
Standardised incidence ratios calculated
#Vasculitis22
Results
153 cancer cases in 135 patients
#Vasculitis22
There was differences in cancer overall incidence in the RCTs.
Also differences in cancer overall incidence according to type of immunosuppression used.
Difference in types of cancer seen.
#Vasculitis22
Increased standardised incidence ratio shown below.
Increased risk was only observed in on melanoma skin cancer.
#Vasculitis22
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.